Table 2.
MRM transitions of vitaminD analogues and internalstandard
| Compounds | Precursor | Product | CE |
|---|---|---|---|
| Vitamin D3 |
385.3 |
159.2 |
40 |
| Vitamin D2 |
397.4 |
159.2 |
43 |
| 25OHD3 |
401.3 |
383.1 |
41 |
| 401.3 |
365.1 |
41 |
|
| 401.3 |
159.2 |
45 |
|
| 25OHD2 |
413.3 |
377.2 |
51 |
| 413.3 |
355.5 |
51 |
|
| 413.3 |
383.1 |
35 |
|
| 1α25(OH)2 D3 |
399.1 |
135.1 |
61 |
| 399.1 |
381.1 |
41 |
|
| 1α25(OH)2 D2 |
411.5 |
151.1 |
55 |
| 3-epi-25OHD3 |
401.3 |
383.1 |
41 |
| 401.3 |
365.1 |
41 |
|
| 401.3 |
159.2 |
45 |
|
| 3-epi-25OHD2 |
413.3 |
377.2 |
51 |
| 413.3 |
355.5 |
51 |
|
| 413.3 |
383.1 |
35 |
|
| 7αC4 |
401.3 |
383.1 |
41 |
| 401.3 |
365.1 |
41 |
|
| 401.3 |
159.2 |
45 |
|
| Stanozolol-D3 | 332.2 | 81.2 | 45 |